Inicio
Resultado de la búsqueda
6 búsqueda de la palabra clave 'Cirrhosis'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigaciónIdentification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study / Juan Carlos Restrepo Gutiérrez
Título : Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2021 Títulos uniformes : Journal of Hepatology Idioma : Inglés (eng) Palabras clave : alcohol alcoholic hepatitis alcohol-associated liver disease alcoholic liver disease cirrhosis steroids corticosteroids MELD Maddrey discriminant function Resumen : Background & Aims: Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too sick to benefit from therapy. Herein, we aimed to identify the range of MELD scores within which steroids are effective for AH. Methods: We performed a retrospective, international multicenter cohort study across 4 continents, including 3,380 adults with a clinical and/or histological diagnosis of AH. The main outcome was mortality at 30 days. We used a discrete-time survival analysis model, and MELD cut-offs were established using the transform-the-endpoints method. Results: In our cohort, median age was 49 (40–56) years, 76.5% were male, and 79% had underlying cirrhosis. Median MELD at admission was 24 (19–29). Survival was 88% (87–89) at 30 days, 77% (76–78) at 90 days, and 72% (72–74) at 180 days. A total of 1,225 patients received corticosteroids. In an adjusted-survival-model, corticosteroid use decreased 30-day mortality by 41% (hazard ratio [HR] 0.59; 0.47–0.74; p 51. The type of corticosteroids used (prednisone, prednisolone, or methylprednisolone) was not associated with survival benefit (p = 0.247). Conclusion: Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39. Mención de responsabilidad : Juan Pablo Arab, Luis Antonio Díaz, Natalia Baeza, Francisco Idalsoaga, Eduardo Fuentes-López, Jorge Arnold, Carolina A. Ramírez, Dalia Morales-Arraez, Meritxell Ventura-Cots, Edilmar Alvarado-Tapias, Wei Zhang, Virginia Clark, Douglas Simonetto, Joseph C. Ahn, Seth Buryska, Tej I. Mehta, Horia Stefanescu, Adelina Horhat, Andreea Bumbu, Winston Dunn, Bashar Attar, Rohit Agrawal, Zohaib Syed Haque, Muhammad Majeed, Joaquín Cabezas, Inés García-Carrera, Richard Parker, Berta Cuyàs, Maria Poca, German Soriano, Shiv K. Sarin, Rakhi Maiwall, Prasun K. Jalal, Saba Abdulsada, María Fátima Higuera-de la Tijera, Anand V. Kulkarni, P Nagaraja Rao, Patricia Guerra Salazar, Lubomir Skladaný, Natália Bystrianska, Veronica Prado, Ana Clemente-Sanchez, Diego Rincón, Tehseen Haider, Kristina R. Chacko, Fernando Cairo, Marcela de Sousa Coelho, Gustavo A. Romero30, Florencia D. Pollarsky, Juan Carlos Restrepo, Susana Castro-Sanchez, Luis G. Toro, Pamela Yaquich, Manuel Mendizabal, Maria Laura Garrido, A Referencia : J Hepatol. 2021 Nov;75(5):1026-1033. DOI (Digital Object Identifier) : 10.1016/j.jhep.2021.06.019 PMID : 34166722 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0168827821004396 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5849 Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2021.
Obra : Journal of Hepatology
Idioma : Inglés (eng)
Palabras clave : alcohol alcoholic hepatitis alcohol-associated liver disease alcoholic liver disease cirrhosis steroids corticosteroids MELD Maddrey discriminant function Resumen : Background & Aims: Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too sick to benefit from therapy. Herein, we aimed to identify the range of MELD scores within which steroids are effective for AH. Methods: We performed a retrospective, international multicenter cohort study across 4 continents, including 3,380 adults with a clinical and/or histological diagnosis of AH. The main outcome was mortality at 30 days. We used a discrete-time survival analysis model, and MELD cut-offs were established using the transform-the-endpoints method. Results: In our cohort, median age was 49 (40–56) years, 76.5% were male, and 79% had underlying cirrhosis. Median MELD at admission was 24 (19–29). Survival was 88% (87–89) at 30 days, 77% (76–78) at 90 days, and 72% (72–74) at 180 days. A total of 1,225 patients received corticosteroids. In an adjusted-survival-model, corticosteroid use decreased 30-day mortality by 41% (hazard ratio [HR] 0.59; 0.47–0.74; p 51. The type of corticosteroids used (prednisone, prednisolone, or methylprednisolone) was not associated with survival benefit (p = 0.247). Conclusion: Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39. Mención de responsabilidad : Juan Pablo Arab, Luis Antonio Díaz, Natalia Baeza, Francisco Idalsoaga, Eduardo Fuentes-López, Jorge Arnold, Carolina A. Ramírez, Dalia Morales-Arraez, Meritxell Ventura-Cots, Edilmar Alvarado-Tapias, Wei Zhang, Virginia Clark, Douglas Simonetto, Joseph C. Ahn, Seth Buryska, Tej I. Mehta, Horia Stefanescu, Adelina Horhat, Andreea Bumbu, Winston Dunn, Bashar Attar, Rohit Agrawal, Zohaib Syed Haque, Muhammad Majeed, Joaquín Cabezas, Inés García-Carrera, Richard Parker, Berta Cuyàs, Maria Poca, German Soriano, Shiv K. Sarin, Rakhi Maiwall, Prasun K. Jalal, Saba Abdulsada, María Fátima Higuera-de la Tijera, Anand V. Kulkarni, P Nagaraja Rao, Patricia Guerra Salazar, Lubomir Skladaný, Natália Bystrianska, Veronica Prado, Ana Clemente-Sanchez, Diego Rincón, Tehseen Haider, Kristina R. Chacko, Fernando Cairo, Marcela de Sousa Coelho, Gustavo A. Romero30, Florencia D. Pollarsky, Juan Carlos Restrepo, Susana Castro-Sanchez, Luis G. Toro, Pamela Yaquich, Manuel Mendizabal, Maria Laura Garrido, A Referencia : J Hepatol. 2021 Nov;75(5):1026-1033. DOI (Digital Object Identifier) : 10.1016/j.jhep.2021.06.019 PMID : 34166722 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0168827821004396 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5849 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001787 AC-2021-099 Archivo digital Producción Científica Artículos científicos Disponible 
Título : Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2020 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Palabras clave : Steatosis NAFLD NASH Fatty liver Clinical practice guidance Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis MAFLD Cirrhosis Resumen : Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease, written by Latin-American specialists in different clinical areas, and destined to general practitioners, internal medicine specialists, endocrinologists, diabetologists, gastroenterologists, and hepatologists. The main purpose of this document is to improve patient care and awareness of NAFLD. The information provided in this guidance may also be useful in assisting stakeholders in the decision-making process related to NAFLD. Since new evidence is constantly emerging on different aspects of the disease, updates to this guideline will be required in future. Mención de responsabilidad : Juan Pablo Arab, Melisa Dirchwolf, Mário Reis Álvares-da-Silva, Francisco Barrera, Carlos Benítez, Marlene Castellanos-Fernandez, Graciela Castro-Narro, Norberto Chavez-Tapia, Daniela Chiodi, Helma Cotrim, Kenneth Cusi, Claudia Pinto Marques Souza de Oliveira, Javier Díaz, Eduardo Fassio, Solange Gerona, Marcos Girala, Nelia Hernandez, Sebastián Marciano, Walter Masson, Nahum Méndez-Sánchez, Nathalie Leite, Adelina Lozano, Martín Padilla, Arturo Panduro, Raymundo Paraná, Edison Parise, Marlene Perez, Jaime Poniachik, Juan Carlos Restrepo, Andrés Ruf, Marcelo Silva, Martín Tagle, Monica Tapias, Kenia Torres, Eduardo Vilar-Gomez, José Eduardo Costa Gil, Adrian Gadano, Marco Arrese Referencia : Ann Hepatol. Nov-Dec 2020;19(6):674-690. DOI (Digital Object Identifier) : 10.1016/j.aohep.2020.09.006 PMID : 33031970 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268120301770 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5159 Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2020.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Palabras clave : Steatosis NAFLD NASH Fatty liver Clinical practice guidance Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis MAFLD Cirrhosis Resumen : Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease, written by Latin-American specialists in different clinical areas, and destined to general practitioners, internal medicine specialists, endocrinologists, diabetologists, gastroenterologists, and hepatologists. The main purpose of this document is to improve patient care and awareness of NAFLD. The information provided in this guidance may also be useful in assisting stakeholders in the decision-making process related to NAFLD. Since new evidence is constantly emerging on different aspects of the disease, updates to this guideline will be required in future. Mención de responsabilidad : Juan Pablo Arab, Melisa Dirchwolf, Mário Reis Álvares-da-Silva, Francisco Barrera, Carlos Benítez, Marlene Castellanos-Fernandez, Graciela Castro-Narro, Norberto Chavez-Tapia, Daniela Chiodi, Helma Cotrim, Kenneth Cusi, Claudia Pinto Marques Souza de Oliveira, Javier Díaz, Eduardo Fassio, Solange Gerona, Marcos Girala, Nelia Hernandez, Sebastián Marciano, Walter Masson, Nahum Méndez-Sánchez, Nathalie Leite, Adelina Lozano, Martín Padilla, Arturo Panduro, Raymundo Paraná, Edison Parise, Marlene Perez, Jaime Poniachik, Juan Carlos Restrepo, Andrés Ruf, Marcelo Silva, Martín Tagle, Monica Tapias, Kenia Torres, Eduardo Vilar-Gomez, José Eduardo Costa Gil, Adrian Gadano, Marco Arrese Referencia : Ann Hepatol. Nov-Dec 2020;19(6):674-690. DOI (Digital Object Identifier) : 10.1016/j.aohep.2020.09.006 PMID : 33031970 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268120301770 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5159 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001591 AC-2020-097 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2020-097.pdfAdobe Acrobat PDF
Título : Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH) Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2019 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Palabras clave : Alcohol alcohol use disorder alcohol-related liver disease alcoholic hepatitis alcoholic liver disease cirrhosis clinical practice guidelines corticosteroids Resumen : Alcohol-related liver disease (ALD) is a major cause of advanced chronic liver disease in Latin-America, although data on prevalence is limited. Public health policies aimed at reducing the alarming prevalence of alcohol use disorder in Latin-America should be implemented. ALD comprises a clinical-pathological spectrum that ranges from steatosis, steatohepatitis to advanced forms such as alcoholic hepatitis (AH), cirrhosis and hepatocellular carcinoma. Besides genetic factors, the amount of alcohol consumption is the most important risk factor for the development of ALD. Continuous consumption of more than 3 standard drinks per day in men and more than 2 drinks per day in women increases the risk of developing liver disease. The pathogenesis of ALD is only partially understood and recent translational studies have identified novel therapeutic targets. Early forms of ALD are often missed and most clinical attention is focused on AH, which is defined as an abrupt onset of jaundice and liver-related complications. In patients with potential confounding factors, a transjugular biopsy is recommended. The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed. In both patients with early and severe ALD, prolonged abstinence is the most efficient therapeutic measure to decrease long-term morbidity and mortality. A multidisciplinary team including alcohol addiction specialists is recommended to manage patients with ALD. Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy. Mención de responsabilidad : Juan P Arab, Juan P Roblero, Jose Altamirano, Fernando Bessone, Roberta Chaves Araujo, Fatima Higuera-De la Tijera, Juan Carlos Restrepo, Aldo Torre, Alvaro Urzua, Douglas A Simonetto, Juan G Abraldes, Nahum Méndez-Sánchez, Fernando Contreras, Michael R Lucey, Vijay H Shah, Helena Cortez-Pinto, Ramon Bataller Referencia : Ann Hepatol. 2019 May - Jun;18(3):518-535 DOI (Digital Object Identifier) : 10.1016/j.aohep.2019.04.005 PMID : 31053546 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268119300419 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4250 Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH) [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2019.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Palabras clave : Alcohol alcohol use disorder alcohol-related liver disease alcoholic hepatitis alcoholic liver disease cirrhosis clinical practice guidelines corticosteroids Resumen : Alcohol-related liver disease (ALD) is a major cause of advanced chronic liver disease in Latin-America, although data on prevalence is limited. Public health policies aimed at reducing the alarming prevalence of alcohol use disorder in Latin-America should be implemented. ALD comprises a clinical-pathological spectrum that ranges from steatosis, steatohepatitis to advanced forms such as alcoholic hepatitis (AH), cirrhosis and hepatocellular carcinoma. Besides genetic factors, the amount of alcohol consumption is the most important risk factor for the development of ALD. Continuous consumption of more than 3 standard drinks per day in men and more than 2 drinks per day in women increases the risk of developing liver disease. The pathogenesis of ALD is only partially understood and recent translational studies have identified novel therapeutic targets. Early forms of ALD are often missed and most clinical attention is focused on AH, which is defined as an abrupt onset of jaundice and liver-related complications. In patients with potential confounding factors, a transjugular biopsy is recommended. The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed. In both patients with early and severe ALD, prolonged abstinence is the most efficient therapeutic measure to decrease long-term morbidity and mortality. A multidisciplinary team including alcohol addiction specialists is recommended to manage patients with ALD. Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy. Mención de responsabilidad : Juan P Arab, Juan P Roblero, Jose Altamirano, Fernando Bessone, Roberta Chaves Araujo, Fatima Higuera-De la Tijera, Juan Carlos Restrepo, Aldo Torre, Alvaro Urzua, Douglas A Simonetto, Juan G Abraldes, Nahum Méndez-Sánchez, Fernando Contreras, Michael R Lucey, Vijay H Shah, Helena Cortez-Pinto, Ramon Bataller Referencia : Ann Hepatol. 2019 May - Jun;18(3):518-535 DOI (Digital Object Identifier) : 10.1016/j.aohep.2019.04.005 PMID : 31053546 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268119300419 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4250 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001229 AC-2019-018 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2019-018.pdfAdobe Acrobat PDF
Título : An experience of liver transplantation in Latin America : a medical center in Colombia Otros títulos : Experiencia de trasplante hepático en Latinoamérica: en un centro médico en Colombia Tipo de documento : documento electrónico Autores : Óscar Mauricio Santos Sánchez, ; Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Álvaro Mena Hurtado, ; Carlos Ernesto Guzmán Luna, ; Sergio Iván Hoyos Duque, ; Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2015 Títulos uniformes : Colombia Médica Idioma : Inglés (eng) Palabras clave : Liver transplantation cirrhosis liver graft rejection immunosuppressive Resumen : Objectives: Liver transplantation is the treatment of choice for acute and chronic liver failure, for selected cases of tumors, and for conditions resulting from errors in metabolism. This paper reports the experience of a medical center in Latin America. Methods:Were conducted 305 orthotopic liver transplantations on 284 patients between 2004 and 2010. Of these patients, 241 were adults undergoing their first transplantation. Results: The average age of patients was 52 years old, and 62% of the individuals were male. The most common indication was alcoholic cirrhosis. The rate of patient survival after 1 and 5 years was 82 and 72% respectively. The rate of liver graft survival after 1 and 5 years was 78 and 68% respectively. The main cause of death was sepsis. Complications in the hepatic artery were documented for 5% of the patients. Additionally, 14.5% of the patients had complications in the biliary tract. Infections were found in 41% of the individuals. Acute rejection was observed in 30% of the subjects, and chronic rejection in 3%. Conclusion:In conclusion, liver transplantation at our medical center in Colombia offers good mid-term results, with a complication rate similar to that reported by other centers around the world. Mención de responsabilidad : Oscar Santos, Mauricio Londoño, Juan Marín, Octavio Muñoz, Álvaro Mena, Carlos Guzmán, Sergio Hoyos, Juan Restrepo, María Arbeláez, Gonzalo Correa Referencia : Colomb Med (Cali). 2015 Mar 30;46(1):8-13. DOI (Digital Object Identifier) : 10.25100/cm.v46i1.1400 PMID : 26019379 Derechos de uso : CC BY En línea : https://colombiamedica.univalle.edu.co/index.php/comedica/article/view/1400 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3879 An experience of liver transplantation in Latin America : a medical center in Colombia = Experiencia de trasplante hepático en Latinoamérica: en un centro médico en Colombia [documento electrónico] / Óscar Mauricio Santos Sánchez, ; Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Álvaro Mena Hurtado, ; Carlos Ernesto Guzmán Luna, ; Sergio Iván Hoyos Duque, ; Juan Carlos Restrepo Gutiérrez, . - 2015.
Obra : Colombia Médica
Idioma : Inglés (eng)
Palabras clave : Liver transplantation cirrhosis liver graft rejection immunosuppressive Resumen : Objectives: Liver transplantation is the treatment of choice for acute and chronic liver failure, for selected cases of tumors, and for conditions resulting from errors in metabolism. This paper reports the experience of a medical center in Latin America. Methods:Were conducted 305 orthotopic liver transplantations on 284 patients between 2004 and 2010. Of these patients, 241 were adults undergoing their first transplantation. Results: The average age of patients was 52 years old, and 62% of the individuals were male. The most common indication was alcoholic cirrhosis. The rate of patient survival after 1 and 5 years was 82 and 72% respectively. The rate of liver graft survival after 1 and 5 years was 78 and 68% respectively. The main cause of death was sepsis. Complications in the hepatic artery were documented for 5% of the patients. Additionally, 14.5% of the patients had complications in the biliary tract. Infections were found in 41% of the individuals. Acute rejection was observed in 30% of the subjects, and chronic rejection in 3%. Conclusion:In conclusion, liver transplantation at our medical center in Colombia offers good mid-term results, with a complication rate similar to that reported by other centers around the world. Mención de responsabilidad : Oscar Santos, Mauricio Londoño, Juan Marín, Octavio Muñoz, Álvaro Mena, Carlos Guzmán, Sergio Hoyos, Juan Restrepo, María Arbeláez, Gonzalo Correa Referencia : Colomb Med (Cali). 2015 Mar 30;46(1):8-13. DOI (Digital Object Identifier) : 10.25100/cm.v46i1.1400 PMID : 26019379 Derechos de uso : CC BY En línea : https://colombiamedica.univalle.edu.co/index.php/comedica/article/view/1400 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3879 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000459 AC-2015-012 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2015-012.pdfAdobe Acrobat PDF
Título : Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study Tipo de documento : documento electrónico Autores : Sergio Iván Hoyos Duque, ; Carlos Ernesto Guzmán Luna, ; Álvaro Mena Hurtado, ; Juan Carlos Restrepo Gutiérrez, ; Gonzalo Correa Arango, ; Juan Camilo Pérez Cadavid, Fecha de publicación : 2015 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Palabras clave : Cancer liver transplant cirrhosis biopsy Resumen : Introduction: Hepatocellular carcinoma is the most common primary tumor of the liver and is diagnosed in more than a half million people worldwide each year. This study aims to assess factors associated with the recurrence and survival of patients with hepatocellular carcinoma and liver transplantation in a cohort of patients from Medellín, Colombia. Material and methods. This was a descriptive retrospective study of a consecutive series of liver transplant patients from the Pablo Tobon Uribe Hospital of Medellín from January 2004 to May 2013. Demographic, clinical, imaging, and pathology variables were analyzed. Results: Three hundred thirty liver transplants were performed during the study period, 54 cases (16.4%) had one or more hepatocellular carcinomas in the explant, and 79.6% of these patients were men. Cirrhotic patients had different etiologies, but most of them were due to alcohol abuse (22.2%), followed by hepatitis B virus infection (20.4 %), and hepatitis C virus infection (18.5%). In the pathology specimen, 51.9% had only one focus of hepatocellular carcinoma, 22.2% had two foci and 12.9% had three tumors. Recurrence of hepatocellular carcinoma occurred in 7.4% patients with an average time of 81 months. During follow-up, 25.9% of the patients died in an average time of 67.9 months (CI95 59.1-80.1 months). Conclusion: Recurrence and survival of patients with liver transplantation for hepatocellular carcinoma in this study had a similar behavior as that reported in the world literature. The factors associated with these outcomes were vascular invasion, poor tumor differentiation and satellitosis. Mención de responsabilidad : Sergio Hoyos, Jorge Escobar, Doris Cardona, Carlos Guzmán, Álvaro Mena, Germán Osorio, Camilo Pérez, Juan C Restrepo, Gonzalo Correa Referencia : Ann Hepatol. 2015 Jan-Feb;14(1):58-63. PMID : 25536642 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268119308014 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3871 Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study [documento electrónico] / Sergio Iván Hoyos Duque, ; Carlos Ernesto Guzmán Luna, ; Álvaro Mena Hurtado, ; Juan Carlos Restrepo Gutiérrez, ; Gonzalo Correa Arango, ; Juan Camilo Pérez Cadavid, . - 2015.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Palabras clave : Cancer liver transplant cirrhosis biopsy Resumen : Introduction: Hepatocellular carcinoma is the most common primary tumor of the liver and is diagnosed in more than a half million people worldwide each year. This study aims to assess factors associated with the recurrence and survival of patients with hepatocellular carcinoma and liver transplantation in a cohort of patients from Medellín, Colombia. Material and methods. This was a descriptive retrospective study of a consecutive series of liver transplant patients from the Pablo Tobon Uribe Hospital of Medellín from January 2004 to May 2013. Demographic, clinical, imaging, and pathology variables were analyzed. Results: Three hundred thirty liver transplants were performed during the study period, 54 cases (16.4%) had one or more hepatocellular carcinomas in the explant, and 79.6% of these patients were men. Cirrhotic patients had different etiologies, but most of them were due to alcohol abuse (22.2%), followed by hepatitis B virus infection (20.4 %), and hepatitis C virus infection (18.5%). In the pathology specimen, 51.9% had only one focus of hepatocellular carcinoma, 22.2% had two foci and 12.9% had three tumors. Recurrence of hepatocellular carcinoma occurred in 7.4% patients with an average time of 81 months. During follow-up, 25.9% of the patients died in an average time of 67.9 months (CI95 59.1-80.1 months). Conclusion: Recurrence and survival of patients with liver transplantation for hepatocellular carcinoma in this study had a similar behavior as that reported in the world literature. The factors associated with these outcomes were vascular invasion, poor tumor differentiation and satellitosis. Mención de responsabilidad : Sergio Hoyos, Jorge Escobar, Doris Cardona, Carlos Guzmán, Álvaro Mena, Germán Osorio, Camilo Pérez, Juan C Restrepo, Gonzalo Correa Referencia : Ann Hepatol. 2015 Jan-Feb;14(1):58-63. PMID : 25536642 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268119308014 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3871 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000451 AC-2015-004 Archivo digital Producción Científica Artículos científicos Disponible Permalink
